1n1m › Citations

Crystal structure of human dipeptidyl peptidase IV/CD26 in complex with a substrate analog.

Rasmussen HB, Branner S, Wiberg FC, Wagtmann N
Nat Struct Biol 10 19-25 (2003)
Cited: 215 times
EuropePMC logo PMID: 12483204

Abstract

Dipeptidyl peptidase IV (DPP-IV/CD26) is a multifunctional type II transmembrane serine peptidase. This enzyme contributes to the regulation of various physiological processes, including blood sugar homeostasis, by cleaving peptide hormones, chemokines and neuropeptides. We have determined the 2.5 A structure of the extracellular region of DPP-IV in complex with the inhibitor valine-pyrrolidide. The catalytic site is located in a large cavity formed between the alpha/beta-hydrolase domain and an eight-bladed beta-propeller domain. Both domains participate in inhibitor binding. The structure indicates how substrate specificity is achieved and reveals a new and unexpected opening to the active site.

Reviews - 1n1m mentioned but not cited (1)

  1. Effects of Glycosylation on the Enzymatic Activity and Mechanisms of Proteases. Goettig P. Int J Mol Sci 17 E1969 (2016)

Articles - 1n1m mentioned but not cited (19)

  1. CB-Dock: a web server for cavity detection-guided protein-ligand blind docking. Liu Y, Grimm M, Dai WT, Hou MC, Xiao ZX, Cao Y. Acta Pharmacol Sin 41 138-144 (2020)
  2. Variability in docking success rates due to dataset preparation. Corbeil CR, Williams CI, Labute P. J Comput Aided Mol Des 26 775-786 (2012)
  3. Dipeptidyl peptidases 8 and 9: specificity and molecular characterization compared with dipeptidyl peptidase IV. Bjelke JR, Christensen J, Nielsen PF, Branner S, Kanstrup AB, Wagtmann N, Rasmussen HB. Biochem J 396 391-399 (2006)
  4. BSP-SLIM: a blind low-resolution ligand-protein docking approach using predicted protein structures. Lee HS, Zhang Y. Proteins 80 93-110 (2012)
  5. KLK5 induces shedding of DPP4 from circulatory Th17 cells in type 2 diabetes. Nargis T, Kumar K, Ghosh AR, Sharma A, Rudra D, Sen D, Chakrabarti S, Mukhopadhyay S, Ganguly D, Chakrabarti P. Mol Metab 6 1529-1539 (2017)
  6. Hot spot analysis for driving the development of hits into leads in fragment-based drug discovery. Hall DR, Ngan CH, Zerbe BS, Kozakov D, Vajda S. J Chem Inf Model 52 199-209 (2012)
  7. Ligand deconstruction: Why some fragment binding positions are conserved and others are not. Kozakov D, Hall DR, Jehle S, Luo L, Ochiana SO, Jones EV, Pollastri M, Allen KN, Whitty A, Vajda S. Proc Natl Acad Sci U S A 112 E2585-94 (2015)
  8. Identification of novel human dipeptidyl peptidase-IV inhibitors of natural origin (part I): virtual screening and activity assays. Guasch L, Ojeda MJ, González-Abuín N, Sala E, Cereto-Massagué A, Mulero M, Valls C, Pinent M, Ardévol A, Garcia-Vallvé S, Pujadas G. PLoS One 7 e44971 (2012)
  9. Structures of human DPP7 reveal the molecular basis of specific inhibition and the architectural diversity of proline-specific peptidases. Bezerra GA, Dobrovetsky E, Dong A, Seitova A, Crombett L, Shewchuk LM, Hassell AM, Sweitzer SM, Sweitzer TD, McDevitt PJ, Johanson KO, Kennedy-Wilson KM, Cossar D, Bochkarev A, Gruber K, Dhe-Paganon S. PLoS One 7 e43019 (2012)
  10. Short and simple sequences favored the emergence of N-helix phospho-ligand binding sites in the first enzymes. Longo LM, Petrović D, Kamerlin SCL, Tawfik DS. Proc Natl Acad Sci U S A 117 5310-5318 (2020)
  11. Identification of novel human dipeptidyl peptidase-IV inhibitors of natural origin (Part II): in silico prediction in antidiabetic extracts. Guasch L, Sala E, Ojeda MJ, Valls C, Bladé C, Mulero M, Blay M, Ardévol A, Garcia-Vallvé S, Pujadas G. PLoS One 7 e44972 (2012)
  12. A Non-Perturbative Molecular Grafting Strategy for Stable and Potent Therapeutic Peptide Ligands. Sicinski KM, Montanari V, Raman VS, Doyle JR, Harwood BN, Song YC, Fagan MP, Rios M, Haines DR, Kopin AS, Beinborn M, Kumar K. ACS Cent Sci 7 454-466 (2021)
  13. High-throughput quantum-mechanics/molecular-mechanics (ONIOM) macromolecular crystallographic refinement with PHENIX/DivCon: the impact of mixed Hamiltonian methods on ligand and protein structure. Borbulevych O, Martin RI, Westerhoff LM. Acta Crystallogr D Struct Biol 74 1063-1077 (2018)
  14. Identification of the DPP-IV Inhibitory Peptides from Donkey Blood and Regulatory Effect on the Gut Microbiota of Type 2 Diabetic Mice. Ma C, Liu D, Hao H, Wu X. Foods 11 2148 (2022)
  15. Structure of XC6422 from Xanthomonas campestris at 1.6 A resolution: a small serine alpha/beta-hydrolase. Yang CY, Chin KH, Chou CC, Wang AH, Chou SH. Acta Crystallogr Sect F Struct Biol Cryst Commun 62 498-503 (2006)
  16. A multilayer dynamic perturbation analysis method for predicting ligand-protein interactions. Gu L, Li B, Ming D. BMC Bioinformatics 23 456 (2022)
  17. The dipeptidyl peptidase IV inhibitors vildagliptin and K-579 inhibit a phospholipase C: a case of promiscuous scaffolds in proteins. Chakraborty S, Rendón-Ramírez A, Ásgeirsson B, Dutta M, Ghosh AS, Oda M, Venkatramani R, Rao BJ, Dandekar AM, Goñi FM. F1000Res 2 286 (2013)
  18. Tebrophen--an old polyphenol drug with anticancer potential. Rubelj I, Stepanić V, Jelić D, Vidaček NŠ, Kalajžić AĆ, Ivanković M, Nujić K, Matijašić M, Verbanac D. Molecules 17 7864-7886 (2012)
  19. Three-Dimensional Molecular Modeling of a Diverse Range of SC Clan Serine Proteases. Laskar A, Chatterjee A, Chatterjee S, Rodger EJ. Mol Biol Int 2012 580965 (2012)


Reviews citing this publication (49)

  1. Structure, Function, and Evolution of Coronavirus Spike Proteins. Li F. Annu Rev Virol 3 237-261 (2016)
  2. Receptor recognition mechanisms of coronaviruses: a decade of structural studies. Li F. J Virol 89 1954-1964 (2015)
  3. Bat-to-human: spike features determining 'host jump' of coronaviruses SARS-CoV, MERS-CoV, and beyond. Lu G, Wang Q, Gao GF. Trends Microbiol 23 468-478 (2015)
  4. Pharmacology, physiology, and mechanisms of action of dipeptidyl peptidase-4 inhibitors. Mulvihill EE, Drucker DJ. Endocr Rev 35 992-1019 (2014)
  5. Cut to the chase: a review of CD26/dipeptidyl peptidase-4's (DPP4) entanglement in the immune system. Klemann C, Wagner L, Stephan M, von Hörsten S. Clin Exp Immunol 185 1-21 (2016)
  6. Molecular physiology and modulation of somatodendritic A-type potassium channels. Jerng HH, Pfaffinger PJ, Covarrubias M. Mol Cell Neurosci 27 343-369 (2004)
  7. The metabolic serine hydrolases and their functions in mammalian physiology and disease. Long JZ, Cravatt BF. Chem Rev 111 6022-6063 (2011)
  8. Prolyl peptidases: a serine protease subfamily with high potential for drug discovery. Rosenblum JS, Kozarich JW. Curr Opin Chem Biol 7 496-504 (2003)
  9. Revisiting an old acquaintance: CD26 and its molecular mechanisms in T cell function. Ohnuma K, Dang NH, Morimoto C. Trends Immunol 29 295-301 (2008)
  10. An emerging role of dipeptidyl peptidase 4 (DPP4) beyond glucose control: potential implications in cardiovascular disease. Zhong J, Rao X, Rajagopalan S. Atherosclerosis 226 305-314 (2013)
  11. Pharmacology of dipeptidyl peptidase-4 inhibitors: similarities and differences. Baetta R, Corsini A. Drugs 71 1441-1467 (2011)
  12. Molecular machines for protein degradation. Groll M, Bochtler M, Brandstetter H, Clausen T, Huber R. Chembiochem 6 222-256 (2005)
  13. Inhibitors of dipeptidyl peptidase IV: a novel approach for the prevention and treatment of Type 2 diabetes? Deacon CF, Ahrén B, Holst JJ. Expert Opin Investig Drugs 13 1091-1102 (2004)
  14. DPP4 in cardiometabolic disease: recent insights from the laboratory and clinical trials of DPP4 inhibition. Zhong J, Maiseyeu A, Davis SN, Rajagopalan S. Circ Res 116 1491-1504 (2015)
  15. Regulation of glucose homeostasis by GLP-1. Nadkarni P, Chepurny OG, Holz GG. Prog Mol Biol Transl Sci 121 23-65 (2014)
  16. The dipeptidyl peptidase IV family in cancer and cell biology. Yu DM, Yao TW, Chowdhury S, Nadvi NA, Osborne B, Church WB, McCaughan GW, Gorrell MD. FEBS J 277 1126-1144 (2010)
  17. Dipeptidyl peptidase 4 inhibitors in the treatment of type 2 diabetes mellitus. Deacon CF. Nat Rev Endocrinol 16 642-653 (2020)
  18. Comparative review of dipeptidyl peptidase-4 inhibitors and sulphonylureas. Deacon CF, Lebovitz HE. Diabetes Obes Metab 18 333-347 (2016)
  19. Inhibitor selectivity in the clinical application of dipeptidyl peptidase-4 inhibition. Kirby M, Yu DM, O'Connor S, Gorrell MD. Clin Sci (Lond) 118 31-41 (2009)
  20. Dipeptidyl peptidase IV inhibitors: how do they work as new antidiabetic agents? McIntosh CH, Demuth HU, Pospisilik JA, Pederson R. Regul Pept 128 159-165 (2005)
  21. Implications of DPP4 modification of proteins that regulate stem/progenitor and more mature cell types. Ou X, O'Leary HA, Broxmeyer HE. Blood 122 161-169 (2013)
  22. Cell-surface peptidases. Mentlein R. Int Rev Cytol 235 165-213 (2004)
  23. Regulation of Chemokine Activity - A Focus on the Role of Dipeptidyl Peptidase IV/CD26. Metzemaekers M, Van Damme J, Mortier A, Proost P. Front Immunol 7 483 (2016)
  24. Unravelling the immunological roles of dipeptidyl peptidase 4 (DPP4) activity and/or structure homologue (DASH) proteins. Wagner L, Klemann C, Stephan M, von Hörsten S. Clin Exp Immunol 184 265-283 (2016)
  25. Food protein hydrolysates as a source of dipeptidyl peptidase IV inhibitory peptides for the management of type 2 diabetes. Power O, Nongonierma AB, Jakeman P, FitzGerald RJ. Proc Nutr Soc 73 34-46 (2014)
  26. Recent approaches to medicinal chemistry and therapeutic potential of dipeptidyl peptidase-4 (DPP-4) inhibitors. Patel BD, Ghate MD. Eur J Med Chem 74 574-605 (2014)
  27. Neuropeptidases and the metabolic inactivation of insect neuropeptides. Isaac RE, Bland ND, Shirras AD. Gen Comp Endocrinol 162 8-17 (2009)
  28. Applications of dipeptidyl peptidase IV inhibitors in diabetes mellitus. McIntosh CH, Demuth HU, Kim SJ, Pospisilik JA, Pederson RA. Int J Biochem Cell Biol 38 860-872 (2006)
  29. Fibroblast activation protein-α in fibrogenic disorders and cancer: more than a prolyl-specific peptidase? Juillerat-Jeanneret L, Tafelmeyer P, Golshayan D. Expert Opin Ther Targets 21 977-991 (2017)
  30. Therapeutic assessment of glucagon-like peptide-1 agonists compared with dipeptidyl peptidase IV inhibitors as potential antidiabetic drugs. Mentlein R. Expert Opin Investig Drugs 14 57-64 (2005)
  31. Opportunities for structure-based design of protease-directed drugs. Mittl PR, Grütter MG. Curr Opin Struct Biol 16 769-775 (2006)
  32. Biomarkers and signaling pathways of colorectal cancer stem cells. Abetov D, Mustapova Z, Saliev T, Bulanin D. Tumour Biol 36 1339-1353 (2015)
  33. A comparative study of human betacoronavirus spike proteins: structure, function and therapeutics. Verma J, Subbarao N. Arch Virol 166 697-714 (2021)
  34. Regulation and roles of CD26/DPPIV in hematopoiesis and diseases. Aliyari Serej Z, Ebrahimi Kalan A, Mehdipour A, Nozad Charoudeh H. Biomed Pharmacother 91 88-94 (2017)
  35. What doesn't kill you makes you stranger: Dipeptidyl peptidase-4 (CD26) proteolysis differentially modulates the activity of many peptide hormones and cytokines generating novel cryptic bioactive ligands. Elmansi AM, Awad ME, Eisa NH, Kondrikov D, Hussein KA, Aguilar-Pérez A, Herberg S, Periyasamy-Thandavan S, Fulzele S, Hamrick MW, McGee-Lawrence ME, Isales CM, Volkman BF, Hill WD. Pharmacol Ther 198 90-108 (2019)
  36. Role of Dipeptidyl Peptidase-4 (DPP4) on COVID-19 Physiopathology. Sebastián-Martín A, Sánchez BG, Mora-Rodríguez JM, Bort A, Díaz-Laviada I. Biomedicines 10 2026 (2022)
  37. Dpp4 inhibition as a therapeutic strategy in cardiometabolic disease: Incretin-dependent and -independent function. Gong Q, Rajagopalan S, Zhong J. Int J Cardiol 197 170-179 (2015)
  38. Recent patents of dipeptidyl peptidase IV inhibitors. Mendieta L, Tarrago T, Giralt E. Expert Opin Ther Pat 21 1693-1741 (2011)
  39. DPP-4 inhibitors: a patent review (2012 - 2014). Costante R, Stefanucci A, Carradori S, Novellino E, Mollica A. Expert Opin Ther Pat 25 209-236 (2015)
  40. Known Cellular and Receptor Interactions of Animal and Human Coronaviruses: A Review. Everest H, Stevenson-Leggett P, Bailey D, Bickerton E, Keep S. Viruses 14 351 (2022)
  41. The expression of proline-specific enzymes in the human lung. Vliegen G, Raju TK, Adriaensen D, Lambeir AM, De Meester I. Ann Transl Med 5 130 (2017)
  42. An expanded role for dipeptidyl peptidase 4 in cell regulation. Ropa J, Broxmeyer HE. Curr Opin Hematol 27 215-224 (2020)
  43. Drug development from the bench to the pharmacy: with special reference to dipeptidyl peptidase-4 inhibitor development. Carr RD. Diabet Med 33 718-722 (2016)
  44. Extracellular proteolysis in cancer: Proteases, substrates, and mechanisms in tumor progression and metastasis. Radisky ES. J Biol Chem 300 107347 (2024)
  45. Beyond history and "on a roll": The list of the most well-studied human protein structures and overall trends in the protein data bank. Li ZL, Buck M. Protein Sci 30 745-760 (2021)
  46. Novel DPP-4 inhibitors against diabetes. Liu Y, Hu Y. Future Med Chem 6 793-808 (2014)
  47. The bulky and the sweet: How neutralizing antibodies and glycan receptors compete for virus binding. Dietrich MH, Harprecht C, Stehle T. Protein Sci 26 2342-2354 (2017)
  48. [Dipeptidyl peptidase IV in inflammatory bowel diseases (DPP IV/CD26)]. Pučar LB, Detel D, Varljen J. Arh Hig Rada Toksikol 63 75-100 (2012)
  49. An Update on Dipeptidyl Peptidase-IV Inhibiting Peptides. Sivaraman SA, Sabareesh V. Curr Protein Pept Sci 25 267-285 (2024)

Articles citing this publication (146)

  1. Molecular basis of binding between novel human coronavirus MERS-CoV and its receptor CD26. Lu G, Hu Y, Wang Q, Qi J, Gao F, Li Y, Zhang Y, Zhang W, Yuan Y, Bao J, Zhang B, Shi Y, Yan J, Gao GF. Nature 500 227-231 (2013)
  2. The crystal structure of dipeptidyl peptidase IV (CD26) reveals its functional regulation and enzymatic mechanism. Engel M, Hoffmann T, Wagner L, Wermann M, Heiser U, Kiefersauer R, Huber R, Bode W, Demuth HU, Brandstetter H. Proc Natl Acad Sci U S A 100 5063-5068 (2003)
  3. Dipeptidylpeptidase 4 negatively regulates colony-stimulating factor activity and stress hematopoiesis. Broxmeyer HE, Hoggatt J, O'Leary HA, Mantel C, Chitteti BR, Cooper S, Messina-Graham S, Hangoc G, Farag S, Rohrabaugh SL, Ou X, Speth J, Pelus LM, Srour EF, Campbell TB. Nat Med 18 1786-1796 (2012)
  4. Structural basis of proline-specific exopeptidase activity as observed in human dipeptidyl peptidase-IV. Thoma R, Löffler B, Stihle M, Huber W, Ruf A, Hennig M. Structure 11 947-959 (2003)
  5. DPP10 modulates Kv4-mediated A-type potassium channels. Zagha E, Ozaita A, Chang SY, Nadal MS, Lin U, Saganich MJ, McCormack T, Akinsanya KO, Qi SY, Rudy B. J Biol Chem 280 18853-18861 (2005)
  6. Ligands bind to Sortilin in the tunnel of a ten-bladed beta-propeller domain. Quistgaard EM, Madsen P, Grøftehauge MK, Nissen P, Petersen CM, Thirup SS. Nat Struct Mol Biol 16 96-98 (2009)
  7. Crystal structure of human dipeptidyl peptidase IV in complex with a decapeptide reveals details on substrate specificity and tetrahedral intermediate formation. Aertgeerts K, Ye S, Tennant MG, Kraus ML, Rogers J, Sang BC, Skene RJ, Webb DR, Prasad GS. Protein Sci 13 412-421 (2004)
  8. Caveolin-1 triggers T-cell activation via CD26 in association with CARMA1. Ohnuma K, Uchiyama M, Yamochi T, Nishibashi K, Hosono O, Takahashi N, Kina S, Tanaka H, Lin X, Dang NH, Morimoto C. J Biol Chem 282 10117-10131 (2007)
  9. X-ray structure of Candida antarctica lipase A shows a novel lid structure and a likely mode of interfacial activation. Ericsson DJ, Kasrayan A, Johansson P, Bergfors T, Sandström AG, Bäckvall JE, Mowbray SL. J Mol Biol 376 109-119 (2008)
  10. Inhibition of dipeptidyl-peptidase IV catalyzed peptide truncation by Vildagliptin ((2S)-{[(3-hydroxyadamantan-1-yl)amino]acetyl}-pyrrolidine-2-carbonitrile). Brandt I, Joossens J, Chen X, Maes MB, Scharpé S, De Meester I, Lambeir AM. Biochem Pharmacol 70 134-143 (2005)
  11. CD26 up-regulates expression of CD86 on antigen-presenting cells by means of caveolin-1. Ohnuma K, Yamochi T, Uchiyama M, Nishibashi K, Yoshikawa N, Shimizu N, Iwata S, Tanaka H, Dang NH, Morimoto C. Proc Natl Acad Sci U S A 101 14186-14191 (2004)
  12. Inhibition of Middle East respiratory syndrome coronavirus infection by anti-CD26 monoclonal antibody. Ohnuma K, Haagmans BL, Hatano R, Raj VS, Mou H, Iwata S, Dang NH, Bosch BJ, Morimoto C. J Virol 87 13892-13899 (2013)
  13. Tissue distribution of the novel DPP-4 inhibitor BI 1356 is dominated by saturable binding to its target in rats. Fuchs H, Binder R, Greischel A. Biopharm Drug Dispos 30 229-240 (2009)
  14. Structure of a human A-type potassium channel interacting protein DPPX, a member of the dipeptidyl aminopeptidase family. Strop P, Bankovich AJ, Hansen KC, Garcia KC, Brunger AT. J Mol Biol 343 1055-1065 (2004)
  15. Targeting of cancer‑associated fibroblasts enhances the efficacy of cancer chemotherapy by regulating the tumor microenvironment. Li M, Li M, Yin T, Shi H, Wen Y, Zhang B, Chen M, Xu G, Ren K, Wei Y. Mol Med Rep 13 2476-2484 (2016)
  16. Concentration-dependent plasma protein binding of the novel dipeptidyl peptidase 4 inhibitor BI 1356 due to saturable binding to its target in plasma of mice, rats and humans. Fuchs H, Tillement JP, Urien S, Greischel A, Roth W. J Pharm Pharmacol 61 55-62 (2009)
  17. Stromal cell-derived factors 1alpha and 1beta, inflammatory protein-10 and interferon-inducible T cell chemo-attractant are novel substrates of dipeptidyl peptidase 8. Ajami K, Pitman MR, Wilson CH, Park J, Menz RI, Starr AE, Cox JH, Abbott CA, Overall CM, Gorrell MD. FEBS Lett 582 819-825 (2008)
  18. Peptide substrate profiling defines fibroblast activation protein as an endopeptidase of strict Gly(2)-Pro(1)-cleaving specificity. Edosada CY, Quan C, Tran T, Pham V, Wiesmann C, Fairbrother W, Wolf BB. FEBS Lett 580 1581-1586 (2006)
  19. Involvement of DPP-IV catalytic residues in enzyme-saxagliptin complex formation. Metzler WJ, Yanchunas J, Weigelt C, Kish K, Klei HE, Xie D, Zhang Y, Corbett M, Tamura JK, He B, Hamann LG, Kirby MS, Marcinkeviciene J. Protein Sci 17 240-250 (2008)
  20. The dipeptidyl peptidase-4 inhibitor linagliptin attenuates inflammation and accelerates epithelialization in wounds of diabetic ob/ob mice. Schürmann C, Linke A, Engelmann-Pilger K, Steinmetz C, Mark M, Pfeilschifter J, Klein T, Frank S. J Pharmacol Exp Ther 342 71-80 (2012)
  21. Glycoproteomics and glycomics investigation of membrane N-glycosylproteins from human colon carcinoma cells. Vercoutter-Edouart AS, Slomianny MC, Dekeyzer-Beseme O, Haeuw JF, Michalski JC. Proteomics 8 3236-3256 (2008)
  22. Molecular, functional and structural properties of the prolyl oligopeptidase of Trypanosoma cruzi (POP Tc80), which is required for parasite entry into mammalian cells. Bastos IM, Grellier P, Martins NF, Cadavid-Restrepo G, de Souza-Ault MR, Augustyns K, Teixeira AR, Schrével J, Maigret B, da Silveira JF, Santana JM. Biochem J 388 29-38 (2005)
  23. Inhibition of fibroblast activation protein and dipeptidylpeptidase 4 increases cartilage invasion by rheumatoid arthritis synovial fibroblasts. Ospelt C, Mertens JC, Jüngel A, Brentano F, Maciejewska-Rodriguez H, Huber LC, Hemmatazad H, Wüest T, Knuth A, Gay RE, Michel BA, Gay S, Renner C, Bauer S. Arthritis Rheum 62 1224-1235 (2010)
  24. Induced-fit mechanism for prolyl endopeptidase. Li M, Chen C, Davies DR, Chiu TK. J Biol Chem 285 21487-21495 (2010)
  25. Soluble CD26 / dipeptidyl peptidase IV enhances human lymphocyte proliferation in vitro independent of dipeptidyl peptidase enzyme activity and adenosine deaminase binding. Yu DM, Slaitini L, Gysbers V, Riekhoff AG, Kähne T, Knott HM, De Meester I, Abbott CA, McCaughan GW, Gorrell MD. Scand J Immunol 73 102-111 (2011)
  26. Human dipeptidyl peptidase III acts as a post-proline-cleaving enzyme on endomorphins. Barsun M, Jajcanin N, Vukelić B, Spoljarić J, Abramić M. Biol Chem 388 343-348 (2007)
  27. A novel SUMO1-specific interacting motif in dipeptidyl peptidase 9 (DPP9) that is important for enzymatic regulation. Pilla E, Möller U, Sauer G, Mattiroli F, Melchior F, Geiss-Friedlander R. J Biol Chem 287 44320-44329 (2012)
  28. Choosing a gliptin. Gupta V, Kalra S. Indian J Endocrinol Metab 15 298-308 (2011)
  29. Mechanism of Gly-Pro-pNA cleavage catalyzed by dipeptidyl peptidase-IV and its inhibition by saxagliptin (BMS-477118). Kim YB, Kopcho LM, Kirby MS, Hamann LG, Weigelt CA, Metzler WJ, Marcinkeviciene J. Arch Biochem Biophys 445 9-18 (2006)
  30. Tyrosine 547 constitutes an essential part of the catalytic mechanism of dipeptidyl peptidase IV. Bjelke JR, Christensen J, Branner S, Wagtmann N, Olsen C, Kanstrup AB, Rasmussen HB. J Biol Chem 279 34691-34697 (2004)
  31. N-linked glycosylation of dipeptidyl peptidase IV (CD26): effects on enzyme activity, homodimer formation, and adenosine deaminase binding. Aertgeerts K, Ye S, Shi L, Prasad SG, Witmer D, Chi E, Sang BC, Wijnands RA, Webb DR, Swanson RV. Protein Sci 13 145-154 (2004)
  32. Concerted structural changes in the peptidase and the propeller domains of prolyl oligopeptidase are required for substrate binding. Szeltner Z, Rea D, Juhász T, Renner V, Fülöp V, Polgár L. J Mol Biol 340 627-637 (2004)
  33. Structural definition and substrate specificity of the S28 protease family: the crystal structure of human prolylcarboxypeptidase. Soisson SM, Patel SB, Abeywickrema PD, Byrne NJ, Diehl RE, Hall DL, Ford RE, Reid JC, Rickert KW, Shipman JM, Sharma S, Lumb KJ. BMC Struct Biol 10 16 (2010)
  34. Homology models of dipeptidyl peptidases 8 and 9 with a focus on loop predictions near the active site. Rummey C, Metz G. Proteins 66 160-171 (2007)
  35. Rigidity and flexibility of dipeptidyl peptidase IV: crystal structures of and docking experiments with DPIV. Engel M, Hoffmann T, Manhart S, Heiser U, Chambre S, Huber R, Demuth HU, Bode W. J Mol Biol 355 768-783 (2006)
  36. Flexibility of prolyl oligopeptidase: molecular dynamics and molecular framework analysis of the potential substrate pathways. Fuxreiter M, Magyar C, Juhász T, Szeltner Z, Polgár L, Simon I. Proteins 60 504-512 (2005)
  37. Modulation of Hematopoietic Chemokine Effects In Vitro and In Vivo by DPP-4/CD26. Broxmeyer HE, Capitano M, Campbell TB, Hangoc G, Cooper S. Stem Cells Dev 25 575-585 (2016)
  38. A Chemical Strategy for Protease Substrate Profiling. Griswold AR, Cifani P, Rao SD, Axelrod AJ, Miele MM, Hendrickson RC, Kentsis A, Bachovchin DA. Cell Chem Biol 26 901-907.e6 (2019)
  39. Identification of residues on human receptor DPP4 critical for MERS-CoV binding and entry. Song W, Wang Y, Wang N, Wang D, Guo J, Fu L, Shi X. Virology 471-473 49-53 (2014)
  40. Possible Role of Adenosine in COVID-19 Pathogenesis and Therapeutic Opportunities. Geiger JD, Khan N, Murugan M, Boison D. Front Pharmacol 11 594487 (2020)
  41. The crystal structure of human dipeptidyl peptidase IV (DPPIV) complex with diprotin A. Hiramatsu H, Yamamoto A, Kyono K, Higashiyama Y, Fukushima C, Shima H, Sugiyama S, Inaka K, Shimizu R. Biol Chem 385 561-564 (2004)
  42. Cross-talk between the dipeptidyl peptidase-4 and stromal cell-derived factor-1 in stem cell homing and myocardial repair: Potential impact of dipeptidyl peptidase-4 inhibitors. Anderluh M, Kocic G, Tomovic K, Kocic R, Deljanin-Ilic M, Smelcerovic A. Pharmacol Ther 167 100-107 (2016)
  43. DPP-IV Inhibitory Potentials of Flavonol Glycosides Isolated from the Seeds of Lens culinaris: In Vitro and Molecular Docking Analyses. Kim BR, Kim HY, Choi I, Kim JB, Jin CH, Han AR. Molecules 23 E1998 (2018)
  44. Nuclear localization of CD26 induced by a humanized monoclonal antibody inhibits tumor cell growth by modulating of POLR2A transcription. Yamada K, Hayashi M, Madokoro H, Nishida H, Du W, Ohnuma K, Sakamoto M, Morimoto C, Yamada T. PLoS One 8 e62304 (2013)
  45. Structures and mechanism of dipeptidyl peptidases 8 and 9, important players in cellular homeostasis and cancer. Ross B, Krapp S, Augustin M, Kierfersauer R, Arciniega M, Geiss-Friedlander R, Huber R. Proc Natl Acad Sci U S A 115 E1437-E1445 (2018)
  46. Different modes of dipeptidyl peptidase IV (CD26) inhibition by oligopeptides derived from the N-terminus of HIV-1 Tat indicate at least two inhibitor binding sites. Lorey S, Stöckel-Maschek A, Faust J, Brandt W, Stiebitz B, Gorrell MD, Kähne T, Mrestani-Klaus C, Wrenger S, Reinhold D, Ansorge S, Neubert K. Eur J Biochem 270 2147-2156 (2003)
  47. A comparative study of the binding properties, dipeptidyl peptidase-4 (DPP-4) inhibitory activity and glucose-lowering efficacy of the DPP-4 inhibitors alogliptin, linagliptin, saxagliptin, sitagliptin and vildagliptin in mice. Berger JP, SinhaRoy R, Pocai A, Kelly TM, Scapin G, Gao YD, Pryor KAD, Wu JK, Eiermann GJ, Xu SS, Zhang X, Tatosian DA, Weber AE, Thornberry NA, Carr RD. Endocrinol Diabetes Metab 1 e00002 (2018)
  48. Beyond glycemic control in diabetes mellitus: effects of incretin-based therapies on bone metabolism. Ceccarelli E, Guarino EG, Merlotti D, Patti A, Gennari L, Nuti R, Dotta F. Front Endocrinol (Lausanne) 4 73 (2013)
  49. Structure and catalysis of acylaminoacyl peptidase: closed and open subunits of a dimer oligopeptidase. Harmat V, Domokos K, Menyhárd DK, Palló A, Szeltner Z, Szamosi I, Beke-Somfai T, Náray-Szabó G, Polgár L. J Biol Chem 286 1987-1998 (2011)
  50. Crystal structure and mechanism of tripeptidyl activity of prolyl tripeptidyl aminopeptidase from Porphyromonas gingivalis. Ito K, Nakajima Y, Xu Y, Yamada N, Onohara Y, Ito T, Matsubara F, Kabashima T, Nakayama K, Yoshimoto T. J Mol Biol 362 228-240 (2006)
  51. A Novel Purification Procedure for Active Recombinant Human DPP4 and the Inability of DPP4 to Bind SARS-CoV-2. Xi CR, Di Fazio A, Nadvi NA, Patel K, Xiang MSW, Zhang HE, Deshpande C, Low JKK, Wang XT, Chen Y, McMillan CLD, Isaacs A, Osborne B, Vieira de Ribeiro AJ, McCaughan GW, Mackay JP, Church WB, Gorrell MD. Molecules 25 E5392 (2020)
  52. Anagliptin, a potent dipeptidyl peptidase IV inhibitor: its single-crystal structure and enzyme interactions. Watanabe YS, Yasuda Y, Kojima Y, Okada S, Motoyama T, Takahashi R, Oka M. J Enzyme Inhib Med Chem 30 981-988 (2015)
  53. Building multidimensional biomarker views of type 2 diabetes on the basis of protein microheterogeneity. Borges CR, Oran PE, Buddi S, Jarvis JW, Schaab MR, Rehder DS, Rogers SP, Taylor T, Nelson RW. Clin Chem 57 719-728 (2011)
  54. Spiking the MERS-coronavirus receptor. Bosch BJ, Raj VS, Haagmans BL. Cell Res 23 1069-1070 (2013)
  55. The dimeric transmembrane domain of prolyl dipeptidase DPP-IV contributes to its quaternary structure and enzymatic activities. Chung KM, Cheng JH, Suen CS, Huang CH, Tsai CH, Huang LH, Chen YR, Wang AH, Jiaang WT, Hwang MJ, Chen X. Protein Sci 19 1627-1638 (2010)
  56. Identification and characterization of prokaryotic dipeptidyl-peptidase 5 from Porphyromonas gingivalis. Ohara-Nemoto Y, Rouf SM, Naito M, Yanase A, Tetsuo F, Ono T, Kobayakawa T, Shimoyama Y, Kimura S, Nakayama K, Saiki K, Konishi K, Nemoto TK. J Biol Chem 289 5436-5448 (2014)
  57. 3D-QSAR studies of Dipeptidyl peptidase IV inhibitors using a docking based alignment. Pissurlenkar RR, Shaikh MS, Coutinho EC. J Mol Model 13 1047-1071 (2007)
  58. Discovery of carmegliptin: a potent and long-acting dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. Mattei P, Boehringer M, Di Giorgio P, Fischer H, Hennig M, Huwyler J, Koçer B, Kuhn B, Loeffler BM, Macdonald A, Narquizian R, Rauber E, Sebokova E, Sprecher U. Bioorg Med Chem Lett 20 1109-1113 (2010)
  59. In silico fragment-based discovery of DPP-IV S1 pocket binders. Rummey C, Nordhoff S, Thiemann M, Metz G. Bioorg Med Chem Lett 16 1405-1409 (2006)
  60. The reversed binding of beta-phenethylamine inhibitors of DPP-IV: X-ray structures and properties of novel fragment and elaborated inhibitors. Nordhoff S, Cerezo-Gálvez S, Feurer A, Hill O, Matassa VG, Metz G, Rummey C, Thiemann M, Edwards PJ. Bioorg Med Chem Lett 16 1744-1748 (2006)
  61. Discovery, SAR, and X-ray structure of novel biaryl-based dipeptidyl peptidase IV inhibitors. Qiao L, Baumann CA, Crysler CS, Ninan NS, Abad MC, Spurlino JC, Desjarlais RL, Kervinen J, Neeper MP, Bayoumy SS, Williams R, Deckman IC, Dasgupta M, Reed RL, Huebert ND, Tomczuk BE, Moriarty KJ. Bioorg Med Chem Lett 16 123-128 (2006)
  62. Molecular cloning of the precursor polypeptide of mastoparan B and its putative processing enzyme, dipeptidyl peptidase IV, from the black-bellied hornet, Vespa basalis. Lee VS, Tu WC, Jinn TR, Peng CC, Lin LJ, Tzen JT. Insect Mol Biol 16 231-237 (2007)
  63. Structure of human dipeptidyl peptidase 10 (DPPY): a modulator of neuronal Kv4 channels. Bezerra GA, Dobrovetsky E, Seitova A, Fedosyuk S, Dhe-Paganon S, Gruber K. Sci Rep 5 8769 (2015)
  64. Contribution of site-specific PEGylation to the dipeptidyl peptidase IV stability of glucose-dependent insulinotropic polypeptide. Salhanick AI, Clairmont KB, Buckholz TM, Pellegrino CM, Ha S, Lumb KJ. Bioorg Med Chem Lett 15 4114-4117 (2005)
  65. Crystal structure and biochemical properties of a novel thermostable esterase containing an immunoglobulin-like domain. Levisson M, Sun L, Hendriks S, Swinkels P, Akveld T, Bultema JB, Barendregt A, van den Heuvel RH, Dijkstra BW, van der Oost J, Kengen SW. J Mol Biol 385 949-962 (2009)
  66. Dipeptidyl aminopeptidase IV from Stenotrophomonas maltophilia exhibits activity against a substrate containing a 4-hydroxyproline residue. Nakajima Y, Ito K, Toshima T, Egawa T, Zheng H, Oyama H, Wu YF, Takahashi E, Kyono K, Yoshimoto T. J Bacteriol 190 7819-7829 (2008)
  67. Discovery of potent, selective, and orally bioavailable oxadiazole-based dipeptidyl peptidase IV inhibitors. Xu J, Wei L, Mathvink RJ, Edmondson SD, Eiermann GJ, He H, Leone JF, Leiting B, Lyons KA, Marsilio F, Patel RA, Patel SB, Petrov A, Scapin G, Wu JK, Thornberry NA, Weber AE. Bioorg Med Chem Lett 16 5373-5377 (2006)
  68. Glutamic acid analogues as potent dipeptidyl peptidase IV and 8 inhibitors. Lu IL, Lee SJ, Tsu H, Wu SY, Kao KH, Chien CH, Chang YY, Chen YS, Cheng JH, Chang CN, Chen TW, Chang SP, Chen X, Jiaang WT. Bioorg Med Chem Lett 15 3271-3275 (2005)
  69. KR-62436, 6-{2-[2-(5-cyano-4,5-dihydropyrazol-1-yl)-2-oxoethylamino]ethylamino}nicotinonitrile, is a novel dipeptidyl peptidase-IV (DPP-IV) inhibitor with anti-hyperglycemic activity. Kim KR, Rhee SD, Kim HY, Jung WH, Yang SD, Kim SS, Ahn JH, Cheon HG. Eur J Pharmacol 518 63-70 (2005)
  70. The amino terminus extension in the long dipeptidyl peptidase 9 isoform contains a nuclear localization signal targeting the active peptidase to the nucleus. Justa-Schuch D, Möller U, Geiss-Friedlander R. Cell Mol Life Sci 71 3611-3626 (2014)
  71. Trp-Arg-Xaa tripeptides act as uncompetitive-type inhibitors of human dipeptidyl peptidase IV. Lan VT, Ito K, Ito S, Kawarasaki Y. Peptides 54 166-170 (2014)
  72. 1-((S)-gamma-substituted prolyl)-(S)-2-cyanopyrrolidine as a novel series of highly potent DPP-IV inhibitors. Sakashita H, Kitajima H, Nakamura M, Akahoshi F, Hayashi Y. Bioorg Med Chem Lett 15 2441-2445 (2005)
  73. Cleavage-site specificity of prolyl endopeptidase FAP investigated with a full-length protein substrate. Huang CH, Suen CS, Lin CT, Chien CH, Lee HY, Chung KM, Tsai TY, Jiaang WT, Hwang MJ, Chen X. J Biochem 149 685-692 (2011)
  74. Crystal structures of Trypanosoma brucei oligopeptidase B broaden the paradigm of catalytic regulation in prolyl oligopeptidase family enzymes. Canning P, Rea D, Morty RE, Fülöp V. PLoS One 8 e79349 (2013)
  75. Insulin-dependent phosphorylation of DPP IV in liver. Evidence for a role of compartmentalized c-Src. Bilodeau N, Fiset A, Poirier GG, Fortier S, Gingras MC, Lavoie JN, Faure RL. FEBS J 273 992-1003 (2006)
  76. Synthesis and structure-activity relationships of potent 3- or 4-substituted-2-cyanopyrrolidine dipeptidyl peptidase IV inhibitors. Fukushima H, Hiratate A, Takahashi M, Saito M, Munetomo E, Kitano K, Saito H, Takaoka Y, Yamamoto K. Bioorg Med Chem 12 6053-6061 (2004)
  77. A rare variant in human fibroblast activation protein associated with ER stress, loss of enzymatic function and loss of cell surface localisation. Osborne B, Yao TW, Wang XM, Chen Y, Kotan LD, Nadvi NA, Herdem M, McCaughan GW, Allen JD, Yu DM, Topaloglu AK, Gorrell MD. Biochim Biophys Acta 1844 1248-1259 (2014)
  78. Purification and characterization of human prolyl dipeptidase DPP8 in Sf9 insect cells. Chen YS, Chien CH, Goparaju CM, Hsu JT, Liang PH, Chen X. Protein Expr Purif 35 142-146 (2004)
  79. 3D-QSAR studies on fluoropyrrolidine amides as dipeptidyl peptidase IV inhibitors by CoMFA and CoMSIA. Zeng J, Liu G, Tang Y, Jiang H. J Mol Model 13 993-1000 (2007)
  80. Serum and intestinal dipeptidyl peptidase IV (DPP IV/CD26) activity in children with celiac disease. Detel D, Persić M, Varljen J. J Pediatr Gastroenterol Nutr 45 65-70 (2007)
  81. Lead optimization of [(S)-gamma-(arylamino)prolyl]thiazolidine focused on gamma-substituent: Indoline compounds as potent DPP-IV inhibitors. Sakashita H, Akahoshi F, Yoshida T, Kitajima H, Hayashi Y, Ishii S, Takashina Y, Tsutsumiuchi R, Ono S. Bioorg Med Chem 15 641-655 (2007)
  82. New fluorinated pyrrolidine and azetidine amides as dipeptidyl peptidase IV inhibitors. Hulin B, Cabral S, Lopaze MG, Van Volkenburg MA, Andrews KM, Parker JC. Bioorg Med Chem Lett 15 4770-4773 (2005)
  83. S46 peptidases are the first exopeptidases to be members of clan PA. Sakamoto Y, Suzuki Y, Iizuka I, Tateoka C, Roppongi S, Fujimoto M, Inaka K, Tanaka H, Masaki M, Ohta K, Okada H, Nonaka T, Morikawa Y, Nakamura KT, Ogasawara W, Tanaka N. Sci Rep 4 4977 (2014)
  84. Systematic analysis of a dipeptide library for inhibitor development using human dipeptidyl peptidase IV produced by a Saccharomyces cerevisiae expression system. Hikida A, Ito K, Motoyama T, Kato R, Kawarasaki Y. Biochem Biophys Res Commun 430 1217-1222 (2013)
  85. A three-dimensional pharmacophore model for dipeptidyl peptidase IV inhibitors. Lu IL, Tsai KC, Chiang YK, Jiaang WT, Wu SH, Mahindroo N, Chien CH, Lee SJ, Chen X, Chao YS, Wu SY. Eur J Med Chem 43 1603-1611 (2008)
  86. Characterisation of human dipeptidyl peptidase IV expressed in Pichia pastoris. A structural and mechanistic comparison between the recombinant human and the purified porcine enzyme. Bär J, Weber A, Hoffmann T, Stork J, Wermann M, Wagner L, Aust S, Gerhartz B, Demuth HU. Biol Chem 384 1553-1563 (2003)
  87. Novel inhibitor for prolyl aminopeptidase from Serratia marcescens and studies on the mechanism of substrate recognition of the enzyme using the inhibitor. Inoue T, Ito K, Tozaka T, Hatakeyama S, Tanaka N, Nakamura KT, Yoshimoto T. Arch Biochem Biophys 416 147-154 (2003)
  88. Predicting DPP-IV inhibitors with machine learning approaches. Cai J, Li C, Liu Z, Du J, Ye J, Gu Q, Xu J. J Comput Aided Mol Des 31 393-402 (2017)
  89. Cell surface adenosine deaminase binds and stimulates plasminogen activation on 1-LN human prostate cancer cells. Gonzalez-Gronow M, Hershfield MS, Arredondo-Vega FX, Pizzo SV. J Biol Chem 279 20993-20998 (2004)
  90. Crystal structure of Porphyromonas gingivalis dipeptidyl peptidase 4 and structure-activity relationships based on inhibitor profiling. Rea D, Van Elzen R, De Winter H, Van Goethem S, Landuyt B, Luyten W, Schoofs L, Van Der Veken P, Augustyns K, De Meester I, Fülöp V, Lambeir AM. Eur J Med Chem 139 482-491 (2017)
  91. Crystal structures of a bacterial dipeptidyl peptidase IV reveal a novel substrate recognition mechanism distinct from that of mammalian orthologues. Roppongi S, Suzuki Y, Tateoka C, Fujimoto M, Morisawa S, Iizuka I, Nakamura A, Honma N, Shida Y, Ogasawara W, Tanaka N, Sakamoto Y, Nonaka T. Sci Rep 8 2714 (2018)
  92. Discovery of new binding elements in DPP-4 inhibition and their applications in novel DPP-4 inhibitor design. Liang GB, Qian X, Biftu T, Singh S, Gao YD, Scapin G, Patel S, Leiting B, Patel R, Wu J, Zhang X, Thornberry NA, Weber AE. Bioorg Med Chem Lett 18 3706-3710 (2008)
  93. Expression, purification and preliminary crystallographic analysis of oligopeptidase B from Trypanosoma brucei. Rea D, Hazell C, Andrews NW, Morty RE, Fülöp V. Acta Crystallogr Sect F Struct Biol Cryst Commun 62 808-810 (2006)
  94. Potent non-nitrile dipeptidic dipeptidyl peptidase IV inhibitors. Simpkins LM, Bolton S, Pi Z, Sutton JC, Kwon C, Zhao G, Magnin DR, Augeri DJ, Gungor T, Rotella DP, Sun Z, Liu Y, Slusarchyk WS, Marcinkeviciene J, Robertson JG, Wang A, Robl JA, Atwal KS, Zahler RL, Parker RA, Kirby MS, Hamann LG. Bioorg Med Chem Lett 17 6476-6480 (2007)
  95. Role of a propeller loop in the quaternary structure and enzymatic activity of prolyl dipeptidases DPP-IV and DPP9. Tang HK, Chen KC, Liou GG, Cheng SC, Chien CH, Tang HY, Huang LH, Chang HP, Chou CY, Chen X. FEBS Lett 585 3409-3414 (2011)
  96. A bacterial acyl aminoacyl peptidase couples flexibility and stability as a result of cold adaptation. Brocca S, Ferrari C, Barbiroli A, Pesce A, Lotti M, Nardini M. FEBS J 283 4310-4324 (2016)
  97. CD26 protease inhibition improves functional response of unfractionated cord blood, bone marrow, and mobilized peripheral blood cells to CXCL12/SDF-1. Christopherson KW, Frank RR, Jagan S, Paganessi LA, Gregory SA, Fung HC. Exp Hematol 40 945-952 (2012)
  98. Discovery of beta-homophenylalanine based pyrrolidin-2-ylmethyl amides and sulfonamides as highly potent and selective inhibitors of dipeptidyl peptidase IV. Nordhoff S, Cerezo-Gálvez S, Deppe H, Hill O, López-Canet M, Rummey C, Thiemann M, Matassa VG, Edwards PJ, Feurer A. Bioorg Med Chem Lett 19 4201-4203 (2009)
  99. His507 of acylaminoacyl peptidase stabilizes the active site conformation, not the catalytic intermediate. Kiss AL, Szeltner Z, Fülöp V, Polgár L. FEBS Lett 571 17-20 (2004)
  100. Inhibition of Dipeptidyl Peptidase-4 by Flavonoids: Structure-Activity Relationship, Kinetics and Interaction Mechanism. Pan J, Zhang Q, Zhang C, Yang W, Liu H, Lv Z, Liu J, Jiao Z. Front Nutr 9 892426 (2022)
  101. Ketopyrrolidines and ketoazetidines as potent dipeptidyl peptidase IV (DPP IV) inhibitors. Ferraris D, Ko YS, Calvin D, Chiou T, Lautar S, Thomas B, Wozniak K, Rojas C, Kalish V, Belyakov S. Bioorg Med Chem Lett 14 5579-5583 (2004)
  102. Structural and mutational analyses of dipeptidyl peptidase 11 from Porphyromonas gingivalis reveal the molecular basis for strict substrate specificity. Sakamoto Y, Suzuki Y, Iizuka I, Tateoka C, Roppongi S, Fujimoto M, Inaka K, Tanaka H, Yamada M, Ohta K, Gouda H, Nonaka T, Ogasawara W, Tanaka N. Sci Rep 5 11151 (2015)
  103. The contribution of Tannerella forsythia dipeptidyl aminopeptidase IV in the breakdown of collagen. Yost S, Duran-Pinedo AE. Mol Oral Microbiol 33 407-419 (2018)
  104. Carboxypeptidase in prolyl oligopeptidase family: Unique enzyme activation and substrate-screening mechanisms. Yadav P, Goyal VD, Gaur NK, Kumar A, Gokhale SM, Jamdar SN, Makde RD. J Biol Chem 294 89-100 (2019)
  105. Diprolyl nitriles as potent dipeptidyl peptidase IV inhibitors. Zhao G, Taunk PC, Magnin DR, Simpkins LM, Robl JA, Wang A, Robertson JG, Marcinkeviciene J, Sitkoff DF, Parker RA, Kirby MS, Hamann LG. Bioorg Med Chem Lett 15 3992-3995 (2005)
  106. Hydrophilic residues surrounding the S1 and S2 pockets contribute to dimerisation and catalysis in human dipeptidyl peptidase 8 (DP8). Pitman MR, Menz RI, Abbott CA. Biol Chem 391 959-972 (2010)
  107. Novel Antibody-Drug Conjugate with Anti-CD26 Humanized Monoclonal Antibody and Transcription Factor IIH (TFIIH) Inhibitor, Triptolide, Inhibits Tumor Growth via Impairing mRNA Synthesis. Hayashi M, Madokoro H, Yamada K, Nishida H, Morimoto C, Sakamoto M, Yanagawa H, Yamada T. Cancers (Basel) 11 E1138 (2019)
  108. Structural Dynamics of DPP-4 and Its Influence on the Projection of Bioactive Ligands. Pantaleão SQ, Philot EA, de Resende-Lara PT, Lima AN, Perahia D, Miteva MA, Scott AL, Honorio KM. Molecules 23 E490 (2018)
  109. 3D structure of the CD26-ADA complex obtained by cryo-EM and single particle analysis. Ludwig K, Fan H, Dobers J, Berger M, Reutter W, Böttcher C. Biochem Biophys Res Commun 313 223-229 (2004)
  110. A novel class of protease targets of phosphatidylethanolamine-binding proteins (PEBP): a study of the acylpeptide hydrolase and the PEBP inhibitor from the archaeon Sulfolobus solfataricus. Palmieri G, Langella E, Gogliettino M, Saviano M, Pocsfalvi G, Rossi M. Mol Biosyst 6 2498-2507 (2010)
  111. C-peptide microheterogeneity in type 2 diabetes populations. Oran PE, Jarvis JW, Borges CR, Nelson RW. Proteomics Clin Appl 4 106-111 (2010)
  112. Catalytically distinct states captured in a crystal lattice: the substrate-bound and scavenger states of acylaminoacyl peptidase and their implications for functionality. Menyhárd DK, Orgován Z, Szeltner Z, Szamosi I, Harmat V. Acta Crystallogr D Biol Crystallogr 71 461-472 (2015)
  113. Discovery of non-covalent dipeptidyl peptidase IV inhibitors which induce a conformational change in the active site. Sheehan SM, Mest HJ, Watson BM, Klimkowski VJ, Timm DE, Cauvin A, Parsons SH, Shi Q, Canada EJ, Wiley MR, Ruehter G, Evers B, Petersen S, Blaszczak LC, Pulley SR, Margolis BJ, Wishart GN, Renson B, Hankotius D, Mohr M, Zechel JC, Michael Kalbfleisch J, Dingess-Hammond EA, Boelke A, Weichert AG. Bioorg Med Chem Lett 17 1765-1768 (2007)
  114. Identification and Characterization of Dipeptidyl Peptidase-IV Inhibitory Peptides from Oat Proteins. Wang W, Liu X, Li Y, You H, Yu Z, Wang L, Liu X, Ding L. Foods 11 1406 (2022)
  115. Novel inhibitor for prolyl tripeptidyl aminopeptidase from Porphyromonas gingivalis and details of substrate-recognition mechanism. Xu Y, Nakajima Y, Ito K, Zheng H, Oyama H, Heiser U, Hoffmann T, Gärtner UT, Demuth HU, Yoshimoto T. J Mol Biol 375 708-719 (2008)
  116. The structural comparison of the bacterial PepX and human DPP-IV reveals sites for the design of inhibitors of PepX activity. Rigolet P, Xi XG, Rety S, Chich JF. FEBS J 272 2050-2059 (2005)
  117. ASP4,000, a novel, selective, dipeptidyl peptidase 4 inhibitor with antihyperglycemic activity. Tanaka-Amino K, Matsumoto K, Hatakeyama Y, Shima I, Takakura S, Muto S. Eur J Pharmacol 590 444-449 (2008)
  118. Design and synthesis of potent amido- and benzyl-substituted cis-3-amino-4-(2-cyanopyrrolidide)pyrrolidinyl DPP-IV inhibitors. Corbett JW, Dirico K, Song W, Boscoe BP, Doran SD, Boyer D, Qiu X, Ammirati M, Vanvolkenburg MA, McPherson RK, Parker JC, Cox ED. Bioorg Med Chem Lett 17 6707-6713 (2007)
  119. Novel N-substituted aminobenzamide scaffold derivatives targeting the dipeptidyl peptidase-IV enzyme. Al-Balas QA, Sowaileh MF, Hassan MA, Qandil AM, Alzoubi KH, Mhaidat NM, Almaaytah AM, Khabour OF. Drug Des Devel Ther 8 129-163 (2014)
  120. An inhibitory antibody against dipeptidyl peptidase IV improves glucose tolerance in vivo. Tang J, Majeti J, Sudom A, Xiong Y, Lu M, Liu Q, Higbee J, Zhang Y, Wang Y, Wang W, Cao P, Xia Z, Johnstone S, Min X, Yang X, Shao H, Yu T, Sharkov N, Walker N, Tu H, Shen W, Wang Z. J Biol Chem 288 1307-1316 (2013)
  121. Bicyclic cyanothiazolidines as novel dipeptidyl peptidase 4 inhibitors. Betancort JM, Winn DT, Liu R, Xu Q, Liu J, Liao W, Chen SH, Carney D, Hanway D, Schmeits J, Li X, Gordon E, Campbell DA. Bioorg Med Chem Lett 19 4437-4440 (2009)
  122. Chemoproteomic identification of a DPP4 homolog in Bacteroides thetaiotaomicron. Keller LJ, Nguyen TH, Liu LJ, Hurysz BM, Lakemeyer M, Guerra M, Gelsinger DJ, Chanin R, Ngo N, Lum KM, Faucher F, Ipock P, Niphakis MJ, Bhatt AS, O'Donoghue AJ, Huang KC, Bogyo M. Nat Chem Biol 19 1469-1479 (2023)
  123. Ligand-induced conformational changes in prolyl oligopeptidase: a kinetic approach. Van Elzen R, Schoenmakers E, Brandt I, Van Der Veken P, Lambeir AM. Protein Eng Des Sel 30 217-224 (2017)
  124. Novel N-substituted 4-hydrazino piperidine derivative as a dipeptidyl peptidase IV inhibitor. Gupta RC, Chhipa L, Mandhare AB, Zambad SP, Chauthaiwale V, Nadkarni SS, Dutt C. Bioorg Med Chem Lett 19 5021-5025 (2009)
  125. Possible ligand release pathway of dipeptidyl peptidase IV investigated by molecular dynamics simulations. Li C, Shen J, Li W, Lu C, Liu G, Tang Y. Proteins 79 1800-1809 (2011)
  126. Structural evidence that puromycin hydrolase is a new type of aminopeptidase with a prolyl oligopeptidase family fold. Matoba Y, Nakayama A, Oda K, Noda M, Kumagai T, Nishimura M, Sugiyama M. Proteins 79 2999-3005 (2011)
  127. Synthesis and biological evaluation of bicyclo[3.3.0] octane derivatives as dipeptidyl peptidase 4 inhibitors for the treatment of type 2 diabetes. Cho TP, Gang LZ, Long YF, Yang W, Qian W, Lei Z, Jing LJ, Ying F, Ke YP, Ying L, Jun F. Bioorg Med Chem Lett 20 3521-3525 (2010)
  128. Discovering novel α-aminoacyl-containing proline derivatives with potent and selective inhibitory activity against dipeptidyl peptidase IV: design, synthesis, biological evaluation, and molecular modeling. Zhang X, Wang J, Su M, Li Z, Li J, Li J, Liu H. Chem Biol Drug Des 80 843-852 (2012)
  129. Effect of identified non-synonymous mutations in DPP4 receptor binding residues among highly exposed human population in Morocco to MERS-CoV through computational approach. Abbad A, Anga L, Faouzi A, Iounes N, Nourlil J. PLoS One 16 e0258750 (2021)
  130. Isoforms of dipeptidyl aminopeptidase IV from Pseudomonas sp. WO24: role of the signal sequence and overexpression in Escherichia coli. Ogasawara W, Tanaka C, Suzuki M, Kobayashi G, Ogawa Y, Okada H, Morikawa Y. Protein Expr Purif 41 241-251 (2005)
  131. Substituted piperidinyl glycinyl 2-cyano-4,5-methano pyrrolidines as potent and stable dipeptidyl peptidase IV inhibitors. Zhao G, Kwon C, Wang A, Robertson JG, Marcinkeviciene J, Parker RA, Kirby MS, Hamann LG. Bioorg Med Chem Lett 23 1622-1625 (2013)
  132. Synthesis and structure-activity relationships of potent 1-(2-substituted-aminoacetyl)-4-fluoro-2-cyanopyrrolidine dipeptidyl peptidase IV inhibitors. Fukushima H, Hiratate A, Takahashi M, Saito-Hori M, Munetomo E, Kitano K, Saito H, Takaoka Y, Yamamoto K. Chem Pharm Bull (Tokyo) 56 1110-1117 (2008)
  133. A Single Second Shell Amino Acid Determines Affinity and Kinetics of Linagliptin Binding to Type 4 Dipeptidyl Peptidase and Fibroblast Activation Protein. Schnapp G, Hoevels Y, Bakker RA, Schreiner P, Klein T, Nar H. ChemMedChem 16 630-639 (2021)
  134. Analysis of cytokines and trace elements in children with febrile seizures. Chen R, Li S, Wang X, Zhou J, Lu Y, Kang A. Transl Pediatr 9 809-817 (2020)
  135. Crystal structures of human dipeptidyl peptidase IV in its apo and diprotin B-complexed forms. Hiramatsu H, Kyono K, Yamamoto A, Saeki K, Shima H, Sugiyama S, Inaka K, Shimizu R. Acta Biochim Biophys Sin (Shanghai) 39 335-343 (2007)
  136. Distal mutation V486M disrupts the catalytic activity of DPP4 by affecting the flap of the propeller domain. Li TT, Peng C, Wang JQ, Xu ZJ, Su MB, Li J, Zhu WL, Li JY. Acta Pharmacol Sin 43 2147-2155 (2022)
  137. Fly DPP10 acts as a channel ancillary subunit and possesses peptidase activity. Shiina Y, Muto T, Zhang Z, Baihaqie A, Yoshizawa T, Lee HI, Park E, Tsukiji S, Takimoto K. Sci Rep 6 26290 (2016)
  138. Isolation of dipeptidyl peptidase IV (DP 4) isoforms from porcine kidney by preparative isoelectric focusing to improve crystallization. Wagner L, Wermann M, Rosche F, Rahfeld JU, Hoffmann T, Demuth HU. Biol Chem 392 665-677 (2011)
  139. One Health and Cattle Genetic Resources: Mining More than 500 Cattle Genomes to Identify Variants in Candidate Genes Potentially Affecting Coronavirus Infections. Bovo S, Schiavo G, Fontanesi L. Animals (Basel) 12 838 (2022)
  140. Seco-prolinenitrile inhibitors of dipeptidyl peptidase IV define minimal pharmacophore requirements at P1. Magnin DR, Taunk PC, Robertson JG, Wang A, Marcinkeviciene J, Kirby MS, Hamann LG. Bioorg Med Chem Lett 16 1731-1734 (2006)
  141. Structural insights of dipeptidyl peptidase-IV inhibitors through molecular dynamics-guided receptor-dependent 4D-QSAR studies. Patil RB, Barbosa EG, Sangshetti JN, Zambre VP, Sawant SD. Mol Divers 22 575-583 (2018)
  142. Xanthene-based near-infrared chromophores for high-contrast fluorescence and photoacoustic imaging of dipeptidyl peptidase 4. Lu P, Dai SM, Zhou H, Wang F, Dong WR, Jiang JH. Chem Sci 15 2221-2228 (2024)
  143. Comparative Binding Study of Gliptins to Bacterial DPP4-like Enzymes for the Treatment of Type 2 Diabetes Mellitus (T2DM). Carpio LE, Olivares M, Benítez-Paez A, Serrano-Candelas E, Barigye SJ, Sanz Y, Gozalbes R. Int J Mol Sci 25 5744 (2024)
  144. Computational Modeling of the Interactions between DPP IV and Hemorphins. Antony P, Baby B, Jobe A, Vijayan R. Int J Mol Sci 25 3059 (2024)
  145. Contribution of amino acids in the active site of dipeptidyl peptidase 4 to the catalytic action of the enzyme. Gnoth K, Bär JW, Rosche F, Rahfeld JU, Demuth HU. PLoS One 19 e0289239 (2024)
  146. DPP8/9 are not Required to Cleave Most Proline-Containing Peptides. Bhattacharjee A, Bachovchin DA. Isr J Chem 63 e202200117 (2023)


Quick links